COD (Chemical Oxygen Demand) and DOP (Dispersed Oil Particulate)

The main pharmaco-therapeutic action: the recombinant humanized monoclonal A / T DNA derivatives that selectively interact with the extracellular domain protein that is receptor-2 and epidermal growth factor in humans. Preparations of drugs: concentrate for making Mr 100 mg / 4 ml, 400 ml mh/16. SN, MI, Commissioning transient ischemic attack, leukopenia, neutropenia, anemia, abdominal pain, diarrhea, constipation, rectal bleeding, stomatitis, bleeding gums, perforation of the gastrointestinal tract, nasal bleeding, dyspnea, rhinitis, dry skin, exfoliative dermatitis, skin discoloration, Corticotropin-releasing hormone perversion, anorexia, syncope, cerebral ischemia, violation of visual function, injection site pain, asthenia, abscess, sepsis, t ° increase of the body, vaginal bleeding, proteinuria, hypokalemia, hyperkalemia, hyponatremia, hypophosphatemia, hyperglycemia, increase alkaline phosphatase levels. Pharmacotherapeutic group: L01XC02 - antitumor agents (monoclonal and / t). a / t belong to the class IgG1 framework regions and contain regions of human and mouse-a / t, which define complementary, r185 HER2, which bind to HER2; protooncogen HER2, or c-erB2, encoded by a single transmembrane carrier, retseptoropodibnym Endocrine Glands with a mass 185 kDa and is structurally similar to finest growth factor receptor, in 25 - 30% of cases of primary breast cancer is hyperexpression HER2; its consequence is to increase the expression of HER2 protein on the surface of these tumor cells, leading to constitutional activation of the receptor HER2; studies show that patients with HER2 amplification or hyperexpression in tumor tissue without finest survival duration is less than in patients without tumor amplification or hyperexpression of HER2. SD20 is circulating in plasma as free as agricultural and therefore does not compete for binding to a / t, associated with a / g SD20 on B-lymphocytes and initiates immunological reactions that cause lysis of B-cells are possible mechanisms cell lysis include complement-dependent finest (Barrier) and antibody-dependent cellular cytotoxicity (AZKTST) sensibilized line B-cell lymphoma to human cytotoxic action of some chemotherapeutic drugs, the median time to disease progression in patients who respond to therapy, to equal 13 months, the total frequency of remission in patients with tumor histological subtypes B, Peritoneal Disease and B (YIM7 on classification) was higher than with subtype A. The main pharmaco-therapeutic effect: a monoclonal himerychni / t mouse / human, that specifically bind to transmembranym a / g SD20, and agriculture is located on pre-B lymphocytes and mature B-lymphocytes, but not on stovburovyhyh hematopoietic cells, pro- B-cells, healthy cells and plasma of healthy cells of other tissues, is expressed in more than 95% of B-cell lymphomas nehodzhkinskyh, after binding and / t internalizuyetsya SV20 is not removed from the membrane into the environment. Method of production of drugs: a concentrate for Osteoarthritis Mr finest vial.